Breast cancers that are triple-negative for the clinical markers ESR1, PGR, and HER2 typically belong to the Basal-like molecular subtype. Defective Rb, p53, and Brca1 pathways are each associated with triple-negative and Basal-like subtypes. Our mouse genetic studies demonstrate that the combined inactivation of Rb and p53 pathways is sufficient to suppress the physiological cell death of mammary involution. Furthermore, concomitant inactivation of all three pathways in mammary epithelium has an additive effect on tumor latency and predisposes highly penetrant, metastatic adenocarcinomas. The tumors are poorly differentiated and have histologic features that are common among human Brca1-mutated tumors, including heterogeneous morphology,...
Breast cancer is the most commonly occurring cancer in women and the second most common cancer overa...
Women with germ-line mutations of the BRCA1 tumor suppressor gene are highly susceptible to breast a...
Thesis (Ph.D.)--University of Rochester. School of Medicine & Dentistry. Dept. of Biomedical Genetic...
<div><p>Breast cancers that are “triple-negative” for the clinical markers ESR1, PGR, and HER2 typic...
Triple negative breast cancer (TNBC) is characterized by multiple genetic events occurring in concer...
Of the estimated 1 million cases of breast cancer diagnosed annually worldwide, it is estimated that...
The claudin-low subtype is a recently identified rare molecular subtype of human breast cancer that ...
While previous studies using genetically engineered mice (GEM) have indicated potential effects of s...
Triple-negative breast cancers lack targeted therapies and are subdivided into molecular subtypes, i...
© 2016 Dr. Lily LeeBreast cancer is the most common cancer to affect women, resulting in over half a...
Breast cancer is the most commonly occurring cancer in women and the second most common cancer overa...
Breast cancer is a highly heterogeneous disease, with several different subtypes being characterized...
Breast cancer is the most commonly occurring cancer in women and the second most common cancer overa...
Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plas...
Introduction.Breast cancer (BC) is a heterogeneous disease, treated as per the predictive role of im...
Breast cancer is the most commonly occurring cancer in women and the second most common cancer overa...
Women with germ-line mutations of the BRCA1 tumor suppressor gene are highly susceptible to breast a...
Thesis (Ph.D.)--University of Rochester. School of Medicine & Dentistry. Dept. of Biomedical Genetic...
<div><p>Breast cancers that are “triple-negative” for the clinical markers ESR1, PGR, and HER2 typic...
Triple negative breast cancer (TNBC) is characterized by multiple genetic events occurring in concer...
Of the estimated 1 million cases of breast cancer diagnosed annually worldwide, it is estimated that...
The claudin-low subtype is a recently identified rare molecular subtype of human breast cancer that ...
While previous studies using genetically engineered mice (GEM) have indicated potential effects of s...
Triple-negative breast cancers lack targeted therapies and are subdivided into molecular subtypes, i...
© 2016 Dr. Lily LeeBreast cancer is the most common cancer to affect women, resulting in over half a...
Breast cancer is the most commonly occurring cancer in women and the second most common cancer overa...
Breast cancer is a highly heterogeneous disease, with several different subtypes being characterized...
Breast cancer is the most commonly occurring cancer in women and the second most common cancer overa...
Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plas...
Introduction.Breast cancer (BC) is a heterogeneous disease, treated as per the predictive role of im...
Breast cancer is the most commonly occurring cancer in women and the second most common cancer overa...
Women with germ-line mutations of the BRCA1 tumor suppressor gene are highly susceptible to breast a...
Thesis (Ph.D.)--University of Rochester. School of Medicine & Dentistry. Dept. of Biomedical Genetic...